CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 84 filers reported holding CRISPR THERAPEUTICS AG in Q4 2017. The put-call ratio across all filers is 0.44 and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2021 | $217,000 | -32.6% | 2,870 | -0.1% | 0.02% | -36.1% |
| Q3 2021 | $322,000 | -30.8% | 2,873 | 0.0% | 0.04% | -30.8% |
| Q2 2021 | $465,000 | +32.9% | 2,873 | 0.0% | 0.05% | +30.0% |
| Q1 2021 | $350,000 | -20.5% | 2,873 | 0.0% | 0.04% | -25.9% |
| Q4 2020 | $440,000 | +83.3% | 2,873 | 0.0% | 0.05% | +54.3% |
| Q3 2020 | $240,000 | +133.0% | 2,873 | 0.0% | 0.04% | +105.9% |
| Q1 2019 | $103,000 | +151.2% | 2,873 | +101.6% | 0.02% | +142.9% |
| Q4 2018 | $41,000 | -34.9% | 1,425 | 0.0% | 0.01% | -30.0% |
| Q3 2018 | $63,000 | -25.0% | 1,425 | 0.0% | 0.01% | -28.6% |
| Q2 2018 | $84,000 | +29.2% | 1,425 | 0.0% | 0.01% | +27.3% |
| Q1 2018 | $65,000 | +97.0% | 1,425 | 0.0% | 0.01% | +120.0% |
| Q4 2017 | $33,000 | +32.0% | 1,425 | 0.0% | 0.01% | +25.0% |
| Q3 2017 | $25,000 | +8.7% | 1,425 | 0.0% | 0.00% | -20.0% |
| Q2 2017 | $23,000 | -25.8% | 1,425 | 0.0% | 0.01% | -28.6% |
| Q1 2017 | $31,000 | – | 1,425 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 3,608,874 | $160,053,562,000 | 54.44% |
| Abingworth LLP | 1,237,202 | $54,858,000 | 32.62% |
| NEA Management Company, LLC | 2,090,678 | $92,722,000 | 4.00% |
| New Leaf Venture Partners, L.L.C. | 444,708 | $19,723,000 | 3.59% |
| EcoR1 Capital, LLC | 500,000 | $22,175,000 | 2.00% |
| ARK Investment Management | 1,453,590 | $64,467,000 | 1.95% |
| CLOUGH CAPITAL PARTNERS L P | 337,731 | $14,978,000 | 1.41% |
| Casdin Capital, LLC | 220,000 | $9,757,000 | 1.19% |
| Valiant Capital Management, L.P. | 271,700 | $12,050,000 | 1.07% |
| Monashee Investment Management LLC | 110,000 | $4,879,000 | 1.03% |